New drug cocktail aims to spare bladders in tough cancer
NCT ID NCT07279597
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs (toripalimab and RC48-ADC) plus radiation in 45 people with HER2-positive muscle-invasive bladder cancer. The goal is to see if this approach can eliminate the cancer and allow patients to keep their bladder after initial chemotherapy. Participants will receive the drugs before, during, and after radiation, with a year of maintenance therapy if they achieve a complete response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
toripalimab and RC48-ADC (a targeted drug) combined with radiotherapy
What this could lead to
If successful, this could offer a way to treat muscle-invasive bladder cancer without removing the bladder, potentially preserving quality of life.
What could go wrong
This is an early phase 2 trial with only 45 participants, so results may not apply to everyone. The combination therapy may cause side effects, and it's not yet proven to be better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••